Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
FireEye (FEYE) Looks Good: Stock Adds 5.8% in Session
FireEye, Inc. was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock, which is trading between the volatile price range of $14.38 to $16.69 in the past one-month time frame, showed a sharp increase yesterday.
The company has seen a mixed track record when it comes to estimate revisions of three increases and one decrease over the past month, while the Zacks Consensus Estimate has remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
FireEye currently has a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
FireEye, Inc. Price and Consensus
FireEye, Inc. Price and Consensus | FireEye, Inc. Quote
A better-ranked stock in the Security industry is Fortinet, Inc. (FTNT - Free Report) , which currently has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is FEYE going up? Or down? Predict to see what others think: Up or Down
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>